Significant advances in the field of prostate caner research have been limited in recent years relative to that of other prevalent cancers mainly because of a dearth of qualified, independently-funded investigators with primary interests in this area. The establishment of SPORE centers of excellence in prostate cancer research have addressed this problem by providing a significant core of physicians and scientists committed to addressing this problem in an interactive and collaborative environment. The two greatest challenges to SPORE centers in the area of cancer development have been 1) to assemble this committed core of investigators from diverse clinical and scientific backgrounds, and to give each member of this core essential background information related to the clinical behavior of prostate cancers and the problems associated with effective management of this disease; and 2) to recruit candidates of unusually high merit to the field of prostate cancer research. The overall goal of our career development program has been to attract highly talented and productive basic and clinical scientists at the postdoctoral level through a national search, and to place these individuals in laboratories taking exciting and imaginative approaches to translational prostate cancer research. During the past 1.5 years, this strategy has brought a wealth of young talent to our institution, and we have used the SPORE Career Development Funds to help attract 45 postdoctoral fellows and 8 new junior faculty members primarily interested in translational prostate cancer research. In addition, the exciting and collaborative intellectual environment generated by our SPORE has attracted 18 established investigators in at least 5 different departments to devote a substantial portion of their research efforts to translational prostate cancer research. Although the availability of SPORE funds for developmental research projects and partial salary support have been useful in attracting both young and established investigators to prostate cancer research, our overall effort in this area has vastly exceeded the direct support provided by the SPORE. We have successfully used SPORE funds to seed recruitment of fellows and junior faculty, and we have leveraged these funds to secure additional support form Baylor College of Medicine, individual departments at the College, and private foundations. Of the total funds expended during the past 2.5 years for hiring and supporting junior faculty and fellows in the area of translational prostate cancer research , more than 80% have come from outside of the SPORE Career Development Program. We estimate that the presence of the prostate SPORE at Baylor College of Medicine has generated an additional 1,000,000.00 per year in Institutional and private foundation support for training fellowships. Over the next five years, we propose to use the strengths of our multi-disciplinary, multi-departmental, and multi-talented SPORE investigators to attract additional fellows, junior faculty, and established investigators to translational prostate cancer research. The vibrant environment surrounding our SPORE conferences, seminars, and research projects should greatly facilitate these efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058204-07S3
Application #
6217440
Study Section
Project Start
1999-06-01
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications